Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Vaccitech Oncology Limited Enters Collaboration with Cancer Research UK to Fund a Phase I/IIa Clinical Trial as First-Line NSCLC Therapy

b3cnewswireDecember 25, 2019

Tag: Vaccitech , NSCLC , VOLT , VTP-600

PharmaSources Customer Service